Alumis Inc. Showcases Breakthrough TYK2 Inhibitor Results for Psoriasis and Lupus

Reuters01-12

<a href="https://laohu8.com/S/ALMS">Alumis Inc.</a> Showcases Breakthrough TYK2 Inhibitor Results for Psoriasis and Lupus

Alumis Inc. has released a corporate presentation detailing recent advancements in its pipeline of precision-engineered TYK2 inhibitors for immune-mediated diseases. The company highlighted positive topline data from its Phase 3 ONWARD1 and ONWARD2 clinical trials, demonstrating that its lead candidate, envudeucitinib, achieved highly statistically significant efficacy in moderate-to-severe plaque psoriasis. The therapy showed rapid onset of action, deep skin clearance at 24 weeks, and improvements in quality of life and itch, with a safety profile consistent with prior studies. The presentation also outlined ongoing development of envudeucitinib for systemic lupus erythematosus and next-generation TYK2 inhibitor programs targeting neuroinflammation and other indications. Additional long-term psoriasis data and lupus trial results are expected in the second half of 2026. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alumis Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2602510564?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-12 21:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602510564","market":"nz","top_or_hot":-1,"title":"Alumis Inc. Showcases Breakthrough TYK2 Inhibitor Results for Psoriasis and Lupus","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ALMS\">Alumis Inc.</a> Showcases Breakthrough TYK2 Inhibitor Results for Psoriasis and Lupus\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Alumis Inc. has released a corporate presentation detailing recent advancements in its pipeline of precision-engineered TYK2 inhibitors for immune-mediated diseases. The company highlighted positive topline data from its Phase 3 ONWARD1 and ONWARD2 clinical trials, demonstrating that its lead candidate, envudeucitinib, achieved highly statistically significant efficacy in moderate-to-severe plaque psoriasis. The therapy showed rapid onset of action, deep skin clearance at 24 weeks, and improvements in quality of life and itch, with a safety profile consistent with prior studies. The presentation also outlined ongoing development of envudeucitinib for systemic lupus erythematosus and next-generation TYK2 inhibitor programs targeting neuroinflammation and other indications. Additional long-term psoriasis data and lupus trial results are expected in the second half of 2026. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alumis Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alumis Inc. Showcases Breakthrough TYK2 Inhibitor Results for Psoriasis and Lupus</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlumis Inc. Showcases Breakthrough TYK2 Inhibitor Results for Psoriasis and Lupus\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-12 21:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ALMS\">Alumis Inc.</a> Showcases Breakthrough TYK2 Inhibitor Results for Psoriasis and Lupus\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Alumis Inc. has released a corporate presentation detailing recent advancements in its pipeline of precision-engineered TYK2 inhibitors for immune-mediated diseases. The company highlighted positive topline data from its Phase 3 ONWARD1 and ONWARD2 clinical trials, demonstrating that its lead candidate, envudeucitinib, achieved highly statistically significant efficacy in moderate-to-severe plaque psoriasis. The therapy showed rapid onset of action, deep skin clearance at 24 weeks, and improvements in quality of life and itch, with a safety profile consistent with prior studies. The presentation also outlined ongoing development of envudeucitinib for systemic lupus erythematosus and next-generation TYK2 inhibitor programs targeting neuroinflammation and other indications. Additional long-term psoriasis data and lupus trial results are expected in the second half of 2026. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alumis Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALMS","symbol_name":"Alumis Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDLbMMvz0:1","article_id":"2602510564","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602510564","pubTimestamp":1768222884,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Alumis Inc. has released a corporate presentation detailing recent advancements in its pipeline of precision-engineered TYK2 inhibitors for immune-mediated diseases. The company highlighted positive topline data from its Phase 3 ONWARD1 and ONWARD2 clinical trials, demonstrating that its lead candidate, envudeucitinib, achieved highly statistically significant efficacy in moderate-to-severe plaque psoriasis. The therapy showed rapid onset of action, deep skin clearance at 24 weeks, and improvements in quality of life and itch, with a safety profile consistent with prior studies. The presentation also outlined ongoing development of envudeucitinib for systemic lupus erythematosus and next-generation TYK2 inhibitor programs targeting neuroinflammation and other indications. Additional long-term psoriasis data and lupus trial results are expected in the second half of 2026. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Techno","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ALMS":"Alumis Inc.","BK4007":"制药"},"translate_title":"Alumis Inc.展示TYK2抑制剂治疗银屑病和狼疮的突破性结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALMS":0.9},"content_text":"Alumis Inc. Showcases Breakthrough TYK2 Inhibitor Results for Psoriasis and Lupus\n    \n\n        Alumis Inc. has released a corporate presentation detailing recent advancements in its pipeline of precision-engineered TYK2 inhibitors for immune-mediated diseases. The company highlighted positive topline data from its Phase 3 ONWARD1 and ONWARD2 clinical trials, demonstrating that its lead candidate, envudeucitinib, achieved highly statistically significant efficacy in moderate-to-severe plaque psoriasis. The therapy showed rapid onset of action, deep skin clearance at 24 weeks, and improvements in quality of life and itch, with a safety profile consistent with prior studies. The presentation also outlined ongoing development of envudeucitinib for systemic lupus erythematosus and next-generation TYK2 inhibitor programs targeting neuroinflammation and other indications. Additional long-term psoriasis data and lupus trial results are expected in the second half of 2026. You can access the full presentation through the link below.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alumis Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602510564","isCrawlerRequest":true}